VIVO - Meridian Bioscience, Inc.
12.56 0.00 (0.00%)
After hours: 4:39PM EDT
| Previous Close | 12.50 |
| Open | 12.47 |
| Bid | 12.53 x 1200 |
| Ask | 12.62 x 800 |
| Day's Range | 12.36 - 12.59 |
| 52 Week Range | 12.30 - 19.84 |
| Volume | 127,554 |
| Avg. Volume | 350,253 |
| Market Cap | 533.664M |
| Beta (3Y Monthly) | 0.35 |
| PE Ratio (TTM) | 20.93 |
| EPS (TTM) | 0.60 |
| Earnings Date | Apr 30, 2019 |
| Forward Dividend & Yield | 0.50 (2.84%) |
| Ex-Dividend Date | 2019-02-01 |
| 1y Target Est | 13.33 |
- Simply Wall St.•3 days ago
A Look At The Intrinsic Value Of Meridian Bioscience, Inc. (NASDAQ:VIVO)
Does the April share price for Meridian Bioscience, Inc. (NASDAQ:VIVO) reflect what it's really worth? Today, we will estimate the stock's intrinsic value by projecting its future cash flows and then discounting them to today's val...
- GlobeNewswire•4 days ago
Meridian Launches a New Inhibitor Tolerant qPCR Reagent to Significantly Simplify Molecular Diagnostic Workflows From Crude Samples
CINCINNATI, April 18, 2019 -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced the launch of its Inhibitor-tolerant qPCR Mix, a novel mix to accelerate workflows and.
- Market Realist•7 days ago
How Does MedMen’s Valuation Multiple Compare with Its Peers?
MedMen Announces Preliminary Q3 Revenues(Continued from Prior Part)Valuation multipleSince the beginning of 2019, MedMen Enterprises (MMEN) (MMNFF) has fallen by 3.6% as of April 12. The decline in MedMen’s stock price has also lowered its
- Market Realist•7 days ago
MedMen Announces Preliminary Q3 Revenues
MedMen Announces Preliminary Q3 RevenuesThird-quarter performance Today, MedMen Enterprises (MMEN) (MMNFF) posted an unaudited revenue of $36.60 million for the third quarter of fiscal 2019, which ended on March 30, 2019. Year-over-year, the
- GlobeNewswire•12 days ago
Meridian Bioscience to Hold Second Quarter 2019 Financial Results Conference Call on April 30, 2019
CINCINNATI, April 10, 2019 -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials will report second quarter.
- GlobeNewswire•21 days ago
Meridian Bioscience Announces Preliminary Second Quarter 2019 Revenue Results; Updates Fiscal 2019 Guidance
Meridian Bioscience, Inc. (VIVO), a provider of diagnostic testing solutions and life science raw materials, today provided a business update including preliminary sales results for its second fiscal quarter and revised financial guidance for fiscal 2019. The Company expects second fiscal quarter 2019 revenues to be approximately $50.0 million, compared to $56.5 million in the second fiscal quarter of 2018. This decline is being driven by Diagnostics segment revenues, which are expected to be down approximately 14% to 16% for the quarter, and relatively flat revenues for the Life Science segment compared to the second fiscal quarter of 2018.
- Simply Wall St.•26 days ago
Why Meridian Bioscience, Inc.’s (NASDAQ:VIVO) Cash Is A Factor You Need To Consider
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Two important questions to ask before you buy Meridian Bioscience, Inc. (NASDAQ:VIVO) is, how it makes money and how it spend...
- Zacks•last month
Here's Why You Should Buy Masimo (MASI) Stock Right Now
Masimo (MASI) announces CE marking of its Next Generation SedLine brain function monitoring for pediatric patients.
- Zacks•last month
BD's Venovo Gets FDA Nod, Interventional Arm to Get a Boost
Becton, Dickinson (BDX) receives a number of regulatory approvals of late.
- Zacks•last month
Here's Why You Should Invest in Stryker (SYK) Stock Right Now
Stryker (SYK) makes a few lucrative acquisitions in recent times.
- Market Realist•2 months ago
VIVO Cannabis Launches New Integrated Medical Cannabis Website
VIVO Cannabis Launches New Integrated Medical Cannabis WebsiteThe announcementThrough its wholly owned subsidiary, Canna Farms Limited, VIVO Cannabis (VIVO) launched an integrated Canna Farms medical cannabis website today. The platform is expected
- Market Realist•2 months ago
TGOD’s Hamilton Facility Receives Organic Certification
TGOD’s Hamilton Facility Receives Organic CertificationThe announcementToday, The Green Organic Dutchman Holdings (TGOD)(TGODF) announced that its cultivation facility in Hamilton received organic certification from Pro-cert Organic Systems, a
- Simply Wall St.•2 months ago
Did Meridian Bioscience, Inc. (NASDAQ:VIVO) Insiders Sell Shares?
It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be remiss not to mention that insider sales haveRead More...
- GlobeNewswire•2 months ago
Meridian Launches New Range of Lyo-Ready PCR Mixes
CINCINNATI, Feb. 07, 2019 -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced that following the successful release of the Lyo-Ready qPCR Mix, Meridian is proud to.
- GlobeNewswire•3 months ago
Market Trends Toward New Normal in Welltower, Ferrari N.V, Caesars Entertainment, Cohu, Mountain Province Diamonds, and Meridian Bioscience — Emerging Consolidated Expectations, Analyst Ratings
NEW YORK, Feb. 04, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Market Realist•3 months ago
VIVO Cannabis and Trulieve Posted Strong Performance Last Week
VIVO Cannabis and Trulieve Posted Strong Performance Last WeekCannabis sector performanceLast week cannabis stocks performed well due to strength in the broader equity market with the S&P 500 Index rising by 1.6%. From January 25 to February 1,
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of VIVO earnings conference call or presentation 24-Jan-19 2:00pm GMT
Q1 2019 Meridian Bioscience Inc Earnings Call
- Zacks•3 months ago
Medical Products Industry Outlook: Plenty of Upside Left
Medical Products Industry Outlook: Plenty of Upside Left
Motley Fool•3 months agoMeridian Bioscience (VIVO) Q1 2019 Earnings Conference Call Transcript
VIVO earnings call for the period ending December 31, 2018.
- Zacks•3 months ago
Meridian Bioscience (VIVO) Tops Q1 Earnings Estimates
Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 11.11% and -0.04%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•3 months ago
Meridian Bioscience: Fiscal 1Q Earnings Snapshot
The Cincinnati-based company said it had profit of 19 cents per share. Earnings, adjusted for non-recurring costs, were 20 cents per share. The results surpassed Wall Street expectations. The average estimate ...
- GlobeNewswire•3 months ago
Meridian Bioscience Reports First Quarter 2019 Operating Results, Declares Regular First Quarter Cash Dividend, and Provides Updated Fiscal 2019 Guidance
CINCINNATI, Jan. 24, 2019 -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the first quarter ended December 31, 2018. First Quarter 2019.
- Simply Wall St.•3 months ago
A Spotlight On Meridian Bioscience, Inc.’s (NASDAQ:VIVO) Fundamentals
Building up an investment case requires looking at a stock holistically. Today I've chosen to put the spotlight on Meridian Bioscience, Inc. (NASDAQ:VIVO) due to its excellent fundamentals in more Read More...
- Zacks•3 months ago
Ericsson (ERIC) to Report Q4 Earnings: What's in the Cards?
Ericsson (ERIC) is likely to report higher year-over-year revenues in the fourth quarter of 2018 on the back of healthy growth dynamics.
- Benzinga•3 months ago
The Daily Biotech Pulse: Amgen Slashes Cholesterol Drug Device Prices By 60%, Takeda Completes Shire Purchase
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech Stocks Hitting 52-week highs on Jan. 7) Axsome Therapeutics Inc (NASDAQ: AXSM ) ( reported positive ...
